Slaughter and May and S&R Associates have advised UK telecom giant Vodafone on a $23 billion deal to merge its India unit with Mumbai-headquartered Idea Cellular, which was represented by AZB & Partners, Vaish Associates Advocates and Bharucha & Partners.

With nearly 400 million customers, the merged entity will reportedly be India’s biggest telecom company, surpassing market leader Bharti Airtel.

The deal, which is expected to be finalised in 2018, shows how India's mobile industry is being transformed by the launch of Reliance Jio Infocomm's 4G mobile broadband network last year, according to Reuters. 

Built at a cost of over $20 billion by Mukesh Ambani, India's richest man, Jio has offered free services for months, reported Reuters. This has forced the country's three largest operators – Bharti, Vodafone and Idea – to cut prices and accept smaller profits, and set off a wave of consolidation.

The AZB team was led by partner Nisha Kaur Uberoi while partners Rajat Sethi and Tanya Aggarwal handled the deal for S&R Associates.

Partners Alka Bharucha and Bomi Daruwala oversaw the transaction for Bharucha and Vaish, respectively.

Related Articles

CC, Slaughters advise as HK-listed SciClone goes private for $1.13 bln

Clifford Chance has advised the Hong Kong-listed SciClone Pharmaceuticals on an offer to take it private by healthcare-focused private equity firm GL Capital, with Slaughter and May acting for the buyer’s financial adviser, Capital Corporation Hong Kong Securities (CICC).

Slaughters, Skadden guide $1.8 bln acquisition of Coke Philippines

by Mari Iwata |

Slaughter and May, Villaraza & Angangco, Skadden, Arps, Slate, Meagher & Flom, SyCip Salazar Hernandez & Gatmaitan have advised the buyers on a $1.8 billion acquisition of Coca-Cola Beverages Philippines (CCBPI) from Coca-Cola.

Goodwin, MoFo, Slaughters guide $478 mln bio-pharma acquisition

by Nimitt Dixit |

U.S. law firm Morrison Foerster has advised Japan’s Kyowa Kirin on its $477.6 million acquisition of British biopharmaceutical company Orchard Therapeutics, which was represented by Goodwin Procter. Slaughter & May was Orchard’s UK legal advisor.